Home / Market News / $DXCM
benzinga Corporate Catalyst Impact 55/100 ● positive

Citigroup Maintains Buy on DexCom, Raises Price Target to $88

Jul 31, 2026, 8:21 PM UTC · Primary ticker $DXCM

This filing discloses that Citigroup analyst Joanne Wuensch has reiterated a 'Buy' rating on DexCom (DXCM) and increased its price target from $84 to $88. This indicates continued analyst confidence in the company's future performance, which could provide a modest positive sentiment for the stock.

Citigroup analyst Joanne Wuensch has maintained a 'Buy' rating on DexCom and raised the price target from $84 to $88. This action signals continued bullish sentiment from a major financial institution regarding DexCom's prospects. For traders, this could lead to a short-term positive bump in DXCM's stock price as investors react to the increased price target and reaffirmed 'Buy' rating. Long-term, it reinforces the investment thesis for DexCom, suggesting analysts believe in its growth trajectory and market position, though the impact is generally moderate unless accompanied by new fundamental information.

$DXCM positive Analyst price target increase
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.